Publication
Real-World Outcomes of Lenvatinib in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multicentre Retrospective Study.
Wing-Lok Chan, Winnie Wing-Yan Tin, Kenneth Chun-Wai Wong, Carol Chi-Hei Kwok, James C H Chow, Tsz-Chim Liu, Gavin Tin-Chun Cheung, Wesley Yuen-Lum Choi, Lok-Sze Joyce Au, Jenny Ching-Hei To, Grace Yuk-Fong Lo, Li-Yu Hou, Kary King-Tung Yeung, Hoi-Leung Leung, Dora Lai-Wan Kwong
- Source
- PubMed
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260917-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Background: Lenvatinib is an established first-line therapy for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); however, real-world data, particularly from Asian populations with long-term follow-up, remain limited. Methods: We conducted a multicentre retrospective cohort…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Thyroid Gland Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available